NYU Professor, best-selling author, business leader and serial entrepreneur Scott Galloway cuts through the biggest stories in tech, business, and investing with unfiltered insights, bold predictions and thoughtful advice. Podcasts include Prof G Markets with co-host Ed Elson, Prof G Conversations and Office Hours with Prof G.
The video examines China's brutally selective 'genius camps' that identify and accelerate elite talent from childhood to power its tech dominance, while analyzing US accusations of covert Chinese nuclear testing amid a collapsing global arms control framework.
Markets are struggling to price AI investments as tech giants deploy unprecedented capital without clear ROI visibility, triggering a violent rotation from growth stocks to certainty plays like Walmart and gold, while Bitcoin crashes as investors prioritize tangible over digital stores of value during geopolitical stress.
Software stocks plummeted 20% amid fears that AI agents will replace SaaS platforms, but the panic mirrors previous overreactions to ChatGPT and TikTok where incumbents ultimately adapted and thrived.
Neera Tanden and Scott Galloway analyze how the Trump administration's tariff policies and contradictory housing stance worsen affordability, while big tech platforms like Uber hike prices post-consolidation, creating an economic squeeze where first-time homebuyers now average age 40 and healthcare costs remain inflated by opaque middlemen.
Derek Thompson argues that despite living in a 'golden age of longevity' where murders, overdoses, suicides, and obesity are simultaneously declining for the first time in history, Americans feel miserable due to algorithm-driven negativity bias and toxic social comparison, while AI tools like Claude Code are poised to fundamentally reshape white-collar work by making every employee an AI manager.
Google's plan to nearly double capital expenditures to $180 billion reignited market fears over AI infrastructure costs, while software stocks cratered on existential business model concerns and the GLP-1 weight-loss market saw Eli Lilly surge as rival Novo Nordisk collapsed.